We develop new
treatments for central
nervous system disorders.

We develop new
treatments for central
nervous system disorders.

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome

June 22, 2021
– Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs–  Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced today that its Phase 2b clinical ... Read more
Read More →

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials

March 23, 2021
– Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners –  Chicago, March 23, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, today ... Read more
Read More →

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

December 15, 2020
– Speak Freely Study Investigates Ecopipam for Childhood-Onset Fluency Disorder –  Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient has been ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy

By emalexadmin | March 9, 2026
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy

By emalexadmin | March 9, 2026
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist ... Read more
Read More →

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization

By emalexadmin | October 8, 2025
Chicago biotech focused on CNS disorders to submit New Drug Application in December for first-in-class treatment CHICAGO — October 8, 2025 — Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational ... Read more
Read More →